Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1386 - Prevention of chemotherapy-induced alopecia in patients with breast or female genital tract cancer using sensor-controlled scalp-cooling


09 Oct 2016


Poster display


Christian Kurbacher


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


C.M. Kurbacher1, S. Herz1, G. Kolberg1, N. Kettelhoit1, A.T. Kurbacher1, C. Schweitzer1, K. Monreal1, J.A. Kurbacher2

Author affiliations

  • 1 Gynecologic Oncology, Gynecologic Center Bonn-Friedensplatz, 53111 - Bonn/DE
  • 2 General Gynecology And Obstetrics, Gynecologic Center Bonn-Friedensplatz, 53111 - Bonn/DE


Abstract 1386


Chemotherapy (Ctx)-induced alopecia (CIA), produces a deep psychological impact in many women involved. Although sensor-controlled scalp cooling (SCSC) is effective in preventing CIA, it is infrequently used in many countries due to physicianś concerns regarding both safety and feasibility. This retrospective analysis was initiated to obtain detailed information about the effectiveness and safety of SCSC using the Paxman system (Paxman, Huddersfield, UK) in female patients (pts) exposed to CIA-inducing Ctx for breast cancer (BC) or genital tract malignancies in the clinical routine.


87 pts who underwent SCSC alongside Ctx from 2014-2016 were identified from our database: BC, 68; epithelial ovarian carcinoma, 14; others, 5; premenopausal, 42; postmenopausal, 45. 63 pts were treated in a curative intent, 24 were treated in a palliative setting; 57 pts were Ctx-naïve, 30 pts had a history of prior Ctx. The following Ctx regimens were used: anthracycline-based (A), 4; taxane-based (T), 21; AT-based, 48; others, 14. Pts were subjected to SCSC during each Ctx cycle. CIA was quantified according to the Dean score (DS) determined 3 wks after the last Ctx cycle. Data were analyzed regarding feasibility indicated by the SCSC completion rate, quality of hair preservation (success: DS 0-2, failure: DS 3-4), reasons of SCSC discontinuation, and safety.


57 pts (64.5%) completed SCSC, with 47 (53.0%) experiencing complete hair preservation (DS 0), and 10 (11.5%) showing partial success (DS 1-2). 30 pts (35.5%) discontinued SCSC, with CIA being the main reason in 21 pts (24.1%). Headache was reported in 4 (5.0%), and local discomfort ("feeling cold") in 3 pts (3.4%). In 2 pts (2.3%), the reason of discontinuation remained unclear. Side effects were all not severe and resolved completely after cessation of SCSC.


In the clinical routine, SCSC using the Paxman system is feasible, safe and effective in order to prevent CIA in pts with BC and female genital tract carcinomas. The treatment success rate in our study is in good agreement with previous reports on SCSC although more pts in the palliative setting or with a history of prior Ctx have been included.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings